# Hypotensive Effect by Activation of NAD(P)H:quinone oxidoreductase 1 via Modulation of eNOS Activity


Chul-Ho Lee DVM, Ph.D





#### **Blood Pressure**

#### What is blood pressure?




#### **Blood pressure regulation mechanism**

- $\sqrt{}$  Baroreceptor & chemoreceptor reflex
- $\sqrt{\text{Renin-angiotensin system (RAS) \& aldosterone}}$
- $\sqrt{\text{Nitric oxide (NO) synthesized by eNOS (NOSIII)}}$

# **Hypertension**


- Raised blood pressure changes the structure of the arteries.
- Hypertension (High blood pressure)
  - √ Systolic blood pressure (SBP) >140 mmHg
  - √ Diastolic blood pressure (DBP) > 90 mmHg
- Raised blood pressure changes the structure of the arteries.
- As a result, risks of stroke, heart disease, kidney failure and other diseases increase, not only in people with hypertension but also in those with average, or even below-average, blood pressure.
- Diet especially too much salt alcohol, lack of exercise and obesity all raise blood pressure.

#### An observed population distribution of SBP




Global Health Risks, 2009, WHO.

#### Deaths attributed to 19 leading risk factors




## Drugs and targets for hypertension




# NAD+ /NADH

#### Nicontinamide adenine dinucleotide

- Coenzyme involving redox reaction to release energy from nutrient in living cells through NADH oxidation by oxidoreductase (malate-aspartate shuttle).
- As a non-redox roles, NAD+ is consumed in ADP-ribose transfer reaction
- Recently sirtuin, NAD-dependent deacetylases, is pharmacologically interesting.






## NADP+ /NADPH


#### Nicontinamide adenine dinucleotide phosphate

- Coenzyme used in anabolic reactions such as lipid and nucleic acid synthesis, cholesterol synthesis, and fatty acis elongation, which required NADPH as a reducing agent. NADPH provides the reducing equivalents for biosynthetic and the oxidation-reduction involved in protecting against the toxicity of ROS, allowing the regeneration of GSH, and also reducing equivalents for cytochrome P450 hydroxylation of aromatic compounds, steroids, alcohol and drugs.
- The oxidative phase of the pentose phosphate pathway is the major source of NADPH in cells (~60% of the NADPH required)



#### NAD(P)H:quinone oxidoreductase (NQO)


- -NQO1 is a ubiquitous homodimeric flavoenzyme initially identified in 1958.
- -NQO encoded by four separate gene loci (Most well characterized members include NQO1 and NQO2)



- -NQO1 catalyzes two-electron reduction of various quinones utilizing NAD(P)H as an electron donor.
- -NQO1-mediated reduction of quinones to hydroquinones is an important cellular defense mechanism against oxidative stress.
- -Studies of NQO1 structure and function have shown that NQO1 is a homodimer that functions via a "ping-pong" mechanism.

# $\beta$ -lapachone ( $\beta$ L)


- -β-lapachone (βL; 3,4-dihydro-2,2-dimethyl-2H-naphtho[1,2-b]pyran-5,6-dione) is isolated from the bark of the Lapacho tree.
- -βL extract has been used as a folk medicine for centuries and initial studies have demonstrated its ability to inhibit tumor growth.
- -βL is a well-known NQO1 substrate, and NQO1 catalyzes the reductive activation of βL which is quinolic chemo-therapeutic compound.



# Previously,

- -It was reported that cellular NAD(P)\*/NAD(P)H ratio was decreased in several disease conditions, such as diabetes-induced hyperglycemia and skeletal muscle dystrophy.
- -Calorie restriction and exercise were reported to lead to an increase in NAD+/NADH ratio, and have beneficial effects on BP in hypertensive patients during clinical trials.

# **Objective**




# SHR: Spontaneous Hypertensionsive Rat





- -In 1963, Dr. Okamoto, Kyoto School of Medicine, from outbred Wistar Kyoto male with marked elevation of blood pressure mated to female with slightly elevated blood pressure. Then, through the brother x sister mating with continu ed selection for spontaneous hyperten sion, SHR were established.
- -As a animal model for genetic hypertension, SHR are being widely used for the efficacy testing of hypertensive drug development.

#### <u>β L reduces blood pressure in SHR and induces</u> <u>NADH oxidation in endothelial cells</u>




#### <u>β L regulates endothelium—dependent</u> vasodilatation through eNOS







#### <u>β L increases eNOS activity via ser<sup>1177</sup></u> <u>phosphorylation</u>




#### Phosphorylation of Akt and AMPK mediate eNOS activation by $\beta$ L




# <u>β L-induced increase of [Ca<sup>2+</sup>]</u> activate Akt/AMPK/eNOS via NQO1 – dependent mechanism




## $\beta$ L activates eNOS in the aorta of SHR




# GTPCH-1 level is dependent on AMPK activity and $\beta$ L inflates GTPCH-1 level in the aorta of SHR by AMPK activation



# NAD+ /NADH & Calcium



Model for the blood pressure regulation mechanism of βL



## Conclusion

- This study is the first to demonstrate that NQO1 activation has hypotensive effect mediated by eNOS activation via modulation of cellular NAD(P)+/NAD(P)H ratio in rat hypertension models.
- Even though it is unclear why NAD(P)+/NAD(P)H is decreased in several pathologic conditions, regulation of NAD(P)+/NAD(P)H ratio by βL via NQO1 activation could be beneficial for improvement of hypertension.

# <u>Acknowledgements</u>

- KRIBB

Yong-Hoon Kim / Jung Hwan Hwang Jung-Ran Noh / Gil-Tae Gang

- Chungnam National University Hospital
  Dr. Minho Shong
- Kyungpook National University Hospital

Dr. In-Kyu Lee / Do Hyun Kim



Thank you!